The efficacy of vortioxetine for the treatment of major depressive disorder

References

• Thapar A, Collishaw S, Pine D, et al. Depression in adolescence. The Lancet 2012;379(9820):1056-67
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Phillip ML. Major depressive disorder: new clinical, neurobiological and treatment perspectives. The Lancet 2012;379(9820):1045-55
   PubMed Web of Science ®Google Scholar
• Von Holff A, Harter M, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013;144:7-15
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Outpatient management of depression. Professional Communications, Inc., USA, 2009, Third edition, 162-3
   Google Scholar
• Kupfer DJ, Frank E, Phillip ML. Major depressive disorder: new clinical, neurobiological and treatment perspectives. The Lancet 2012;379(9820):1045-55
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Available from: www.whocc.no/atc_ddd_index/?code=N06AX&showdescription=yes
   Google Scholar
• Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4 dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54(9):3206-21
   PubMed Web of Science ®Google Scholar
• Sanchez C, Westrich L, Zhong H, et al. In vitro effects of the multimodal antidepressant Lu AA21004 at human and rat 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors, and 5-HT transporters. Eur Neuropsychopharmacol 2012;22(Suppl 2):S245-6
   Google Scholar
• Mork A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodel antidepressant, enhances memory in rats. Pharmacol Biochem Behav 2013;105:41-50
   PubMed Web of Science ®Google Scholar
• Westrich L, Pehrson A, Zhong H, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract 2012;16(Suppl 1):47
   Google Scholar
• Sanchez C, Asin KE, Artigas F, et al. A novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gibbs V, Deeks ED. Vortioxetine: first global approval. Drugs 2014;74(1):135-45
   PubMed Web of Science ®Google Scholar
• Areberg J, Sogaard B, Hojer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 2012;111:198-205
   PubMed Web of Science ®Google Scholar
• Uldam HK, Juhl M, Pedersen H, et al. Biosynthesis and identification of an Noxide N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Drug Metab Dispos 2011;39:2264-74
   PubMed Web of Science ®Google Scholar
• Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012;40:1357-65
   PubMed Web of Science ®Google Scholar
• Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 2013;23:1190-8
   PubMed Web of Science ®Google Scholar
• Wang L, Kuang W, Xu J, et al. Resting-state brain activation correlates with short-time antidepressant treatment outcome in drug-naive patients with MDD. J Int Medical Res 2014;42(4):966-75
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahabaleshwarkar AR, Dragheim M, et al. The efficacy of vortioxetine versus placebo in the treatment of adults with major depressive disorder: Data from 10 short-term studies and a meta-analysis. 52nd Annual meeting of ACNP (8-12 December, Florida, USA) 2013. 142
   Google Scholar
• Randomised placebo-controlled venlafaxine-referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. Available from: http://clinicaltrials.gov/show/NCT00839423
   Google Scholar
• Randomised placebo-controlled duloxetine-referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT00635219
   Google Scholar
• Efficacy study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT00735709
   Google Scholar
• Randomised placebo-controlled duloxetine-referenced study of efficacy and safety of 15 and 20 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults. Available from: http://clinicaltrials.gov/show/NCT01140906
   Google Scholar
• Safety and efficacy of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01153009
   Google Scholar
• Efficacy and safety study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01163266
   Google Scholar
• Efficacy and safety of vortioxetine (Lu AA21004) in treating adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT00672958
   Google Scholar
• Efficacy and safety of vortioxetine (Lu AA21004) in the treatment of patients with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT00672620
   Google Scholar
• Safety and efficacy study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01179516
   Google Scholar
• Randomised placebo-controlled duloxetine-referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients. Available from: http://clinicaltrials.gov/show/NCT00811252
   Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012;15:589-600
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91
   PubMed Web of Science ®Google Scholar
• Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, doubleblind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013;16:313-21
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29:217-26
   PubMed Web of Science ®Google Scholar
• Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9
   PubMed Web of Science ®Google Scholar
• Prakash A, Risser RC, Malinckrodt CH. The impact of analytical method on interpretation of outcome in longitudinal clinical trial. Int. J Pract 2008;62:1147-58
   PubMed Web of Science ®Google Scholar
• Siddiqui O, Hung HM, O’Neil R. MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA database. J Biopharm Stat 2009;19(2):227-46
   PubMed Web of Science ®Google Scholar
• Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-106
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Mahableshwarkar AR, Serenko M, et al. A randomized, double blind, placebo controlled study of the efficacy and safety of vortioxetine 10mg and 20mg in adults with major depressive disorder. In 166th Annual Meeting of the American Psychiatric Association (APA), San Francisco, CA, USA, 18-22 May 2013, Poster NR9-06
   Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A duloxetine referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD. In 166th Annual Meeting of the American Psychiatric Association (APA), San Francisco, CA, USA, 18-22 May 2013, Poster NR9-01
   Google Scholar
• Florea I, Danchenko N, Loft H, et al. The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. 18th Annual international meeting of the International Society of Pharmacoeconomics and Outcomes Research. (May New Orleans, USA) 2013:18-22, PMH55
   Google Scholar
• Open-label safety extension study of 15 and 20 mg of vortioxetine (Lu AA21004) in long-term treatment of major depressive disorder in adults. Available from: http://clinicaltrials.gov/show/NCT01323478
   Google Scholar
• Dunner D, Blier P, Keller M, et al. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry 2007;9(3):214-23
   Google Scholar
• Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an openlabel, flexible- dose, 52-week extension study. Int Clin Psychopharmacol 2014;29:36-44
   Google Scholar
• Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28(10):1717-24
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar A, Jacobsen PL, Serenko M, et al. A randomized, double blind, placebo-controlled study of the efficacy and safety of 2 dose of vortioxetine (LuAA21004) in adults with major depressive disorder. In 166th Annual Meeting of the American Psychiatric Association (APA), San Francisco, CA, USA, 18-22 May 2013, Poster NR9-02
   Google Scholar
• Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, PLACEBO-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29(3):138-49
   PubMed Web of Science ®Google Scholar
• Study of vortioxetine (Lu AA21004) in major depressive disorder in Asian countries. Available from: http://clinicaltrials.gov/show/NCT01571453
   Google Scholar
• Investor Relations. Available from: http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=856580
   Google Scholar
• Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, PLACEBO-controlled clinical trial. Eur Neuropsychopharmacol 2012;22(12):847-57
   PubMed Web of Science ®Google Scholar
• Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: a meta-analyis of the association, its pattern, and specificity. Psychol Bull 1995;117(2):285-305
   PubMed Web of Science ®Google Scholar
• Wallace A, Pehrson AL, Sanchez C, Morilk DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;17(10):1695-706
   PubMed Web of Science ®Google Scholar
• du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014;24:160-71
   Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17(10):1557-67
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2013:1-13
   Google Scholar
• Haggstrom L, Nielsen RZ, Danchenko N, Poulsen L. A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. Eur Neuropsychopharmacol 2013;23(Suppl 2):S412
   Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol 2014;29(1):64-72
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, PLACEBO-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 2014;68(1):49-59
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double blind, PLACEBO-controlled clinical trial in the United States. Eur Neuropsychopharmacol 2012;22(12):858-66
   PubMed Web of Science ®Google Scholar
• Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013;93:493-501
   PubMed Web of Science ®Google Scholar
• Wilson S, Buchbjerg J, Hojer AM, et al. Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study. Eur Neuropsychopharmacol 2013;23(Suppl 2):S195-6
   Google Scholar
• Monti JM, Jantos H. Activation of the serotonin 5-HT3 receptor in the dorsal raphe nucleus suppresses REM sleep in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2008;2:940-7
   Google Scholar
• Strohmaier J, Wust S, Uher R. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. The world J Biological Psychiatry 2011;12(7):28-238
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011;89(1):142-7
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry 2013;202:396-7
   PubMed Web of Science ®Google Scholar
• Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014;37:19-31
   PubMed Web of Science ®Google Scholar
• Haggstrom L, Nielsen RZ, Poulsen L, Danchenko N. A randomised, double blind, active controlled study of vorioxetine (10–20 mg/day) versus agomelatine 25–50 mg/day) in adults with Major Depressive Disorder with inadequate response to antidepressant treatment. Poster presented at 26th Congress of the European College of Neuropsychopharmacology (ECNP); 5–9 October, 2013;Barcelona, Spain
   Google Scholar
• Summary of product characteristic brintellix. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/02717/WC500159449.pdf
   Google Scholar
• Chen G, Lee R, Hojer AM, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013;33:727-36
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28(9):855-74
   PubMed Web of Science ®Google Scholar
• Dhir A. Vortioxetine for the treatment of major depression. Drugs Today (Barc) 2103;49(12):781-90
   Google Scholar
• Wang Y, Wojtkowski T, Agyemang A. Effect of food on the pharmacokinetics of Lu AA21004 in healthy volunteers. J Clin Pharmacol [38th Annu Meet American College of Clinical Pharmacology (Sept 13-Sept 15, San Antonio. Texas 2009;2009:49(Supp 9):1115
   Google Scholar
• Wang Y, Zhang W, Agyemang A, et al. Lack of effect of multiple doses of Lu. AA21004 on the pharmacodynamics and pharmacokinetics of aspirin. J Clin Pharmacol [39th Annu Meet American College of Clinical Pharmacology (Sept 12-Sept 14 Baltimore, Maryland 2010] 2010;50(9):1082
   Google Scholar
• Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults. Available from: http://clinicaltrials.gov/show/NCT00761306
   Google Scholar
• Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in acute treatment of major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT01255787
   Google Scholar
• Safety and tolerability of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials.gov/show/NCT00707980
   Google Scholar
• Open-label safety extension study of 15 and 20 mg of Vortioxetine (Lu AA21004) in long-term treatment of major depressive disorder in adults. Available from: http://clinicaltrials.gov/show/NCT01323478
   Google Scholar
• Safety and tolerability of vortioxetine (LuAA21004) - Open Label Extension Study. Available from: http://clinicaltrials.gov/show/NCT01152996
   Google Scholar
• Effects of Vortioxetine (Lu AA21004) on the concentrations of selected neurotransmitters in healthy male adults. Available from: http://clinicaltrials.gov/show/NCT01299805
   Google Scholar
• Pharmacokinetic properties of Lu AA21004 (Vortioxetine) in healthy young Chinese men and women. Available from: http://clinicaltrials.gov/show/NCT01676571
   Google Scholar
• Exploratory study of the effects of vortioxetine (Lu AA21004) on cognition and blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) signals in subjects remitted from depression and in controls. Available from: http://clinicaltrials.gov/show/NCT01607125
   Google Scholar